Related CAS #
64000-73-3 (free base); 56393-22-7 (2HCl)
Synonym
Pildralazine Free Base; CCRIS5384; CCRIS-5384; CCRIS 5384
IUPAC/Chemical Name
(+-)-1-((6-Hydrazino-3-pyridazinyl)methylamino)-2-propanol
InChi Key
KYIAWOXNPBANEW-UHFFFAOYSA-N
InChi Code
InChI=1S/C8H15N5O/c1-6(14)5-13(2)8-4-3-7(10-9)11-12-8/h3-4,6,14H,5,9H2,1-2H3,(H,10,11)
SMILES Code
CC(O)CN(C1=NN=C(NN)C=C1)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
197.24
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Noack E, Cawello W, Bonn R. Kinetic studies of the tissue binding tendency of the new vasodilator pildralazine. Arzneimittelforschung. 1987 Apr;37(4):407-9. PMID: 3606695.
2: Della Porta G, Dragani TA. Carcinogenicity study in mice on pildralazine, a hydralazinelike antihypertensive compound. J Cancer Res Clin Oncol. 1983;106(2):97-101. doi: 10.1007/BF00395386. PMID: 6630287.
3: Dorigotti L, Carpi C, Bertoli G, Mariani PL. Effects of pildralazine alone and in combination on severe hypertension and cerebrovascular lesions in saline- drinking spontaneously hypertensive rats. Arzneimittelforschung. 1984;34(8):876-9. PMID: 6541924.
4: Chen N, Schoenbach KH, Kolb JF, James Swanson R, Garner AL, Yang J, Joshi RP, Beebe SJ. Leukemic cell intracellular responses to nanosecond electric fields. Biochem Biophys Res Commun. 2004 Apr 30;317(2):421-7. doi: 10.1016/j.bbrc.2004.03.063. PMID: 15063775.
5: Worcel M. Relationship between the direct inhibitory effect of hydralazine and propildazine on arterial smooth muscle contractility and sympathetic innervation. J Pharmacol Exp Ther. 1978 Nov;207(2):320-30. PMID: 712622.
6: Glatt H, Oesch F. Propyldazine is mutagenic in Salmonella typhimurium and Escherichia coli: distinct specificity for strains TA1537 and TA97. Teratog Carcinog Mutagen. 1985;5(5):339-45. doi: 10.1002/tcm.1770050504. PMID: 2867616.
7: Bacher S, Kraupp O, Beck A, Seitelberger R, Raberger G. Altered blood pressure response to propyldazine after repeated oral administration in conscious normotensive dogs: role of the renin-angiotensin system. Basic Res Cardiol. 1984 Sep-Oct;79(5):588-97. doi: 10.1007/BF01910488. PMID: 6391464.
8: Pinza M, Pifferi G. Synthesis and biotransformation of 3-hydrazinopyridazine drugs. Farmaco. 1994 Nov;40(11):683-92. PMID: 7832970.
9: Ventura P, Parravicini F, Simonotti L, Colombo R, Pifferi G. Degradation of propildazine in water. J Pharm Sci. 1981 Mar;70(3):334-6. doi: 10.1002/jps.2600700331. PMID: 7264906.
10: Bacher S, Kraupp O, Beck A, Skoda H, Raberger G. Characterization of vasodilators by comparison of their effects on blood pressure, counterregulation and myocardial oxygen demand in conscious normotensive dogs. Arzneimittelforschung. 1985;35(1A):288-91. PMID: 3885964.
